MARIETTA, Ga., Nov. 26, 2013 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today the summaries of a selection of the seven posters highlighting MiMedx allografts presented at the recent 10th Annual Desert Foot High Risk Diabetic Foot Conference in Phoenix, Arizona.
The posters chronicled the clinical effectiveness of the MiMedx dehydrated human amnion/chorion membrane ("dHACM") allografts and detailed a wide range of wounds and injuries with varying degrees of etiologies. A sampling of the posters presenting dHACM cases and studies, along with a summary of the respective study results and conclusions are as follows:
Parker H. "Pete" Petit, Chairman and CEO, said, "The independent study abstracts presented at Desert Foot are further indications of the clinical and cost effectiveness of our dHACM allografts. When a graft achieves wound closure with these metrics, we believe we are best serving the clinical and economic needs of our market. We continue to champion the cause of reducing costs of wound closure, and these abstracts highlight those goals."
Bill Taylor, President and COO, stated, "In the collective body of work forming the basis for the seven MiMedx poster abstracts, the EpiFix® data involved the treatment of 55 patients. In the combined studies, an average number of 3.5 EpiFix® applications were applied to achieve healed ulcers, and the average number of weeks to achieve healing using the MiMedx allografts was 6.8 weeks. These results mirror the impressive results our dHACM allografts have achieved in prior Randomized Controlled Trials, cross over trials and follow-up studies. "
MiMedx® is an integrated developer, manufacturer and marketer of patent protected regenerative biomaterial products and bioimplants processed from human amniotic membrane. "Innovations in Regenerative Biomaterials" is the framework behind our mission to give physicians products and tissues to help the body heal itself. Our biomaterial platform technologies include AmnioFix® and EpiFix®, our tissue technologies processed from human amniotic membrane that is derived from donated placentas. Through our donor program, mothers delivering full-term Caesarean section births can elect in advance of delivery to donate the placenta in lieu of having it discarded as medical waste. We process the human amniotic membrane utilizing our proprietary PURION® process, to produce a safe and effective implant. MiMedx® is the leading supplier of amniotic tissue, having supplied over 200,000 allografts to date to distributors and OEMs for application in the Wound Care, Surgical, Sports Medicine, Ophthalmic and Dental sectors of healthcare.
Safe Harbor Statement
This press release includes statements that look forward in time or that express management's beliefs, expectations or hopes. Such statements are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to the clinical and cost effectiveness of EpiFix® and AmnioFix®. These statements are based on current information and belief, and are not guarantees of future performance. Among the risks and uncertainties that could cause actual results to differ materially from those indicated by such forward-looking statements include the potential that EpiFix® and AmnioFix® will not perform as expected or will not gain acceptance in the medical community, and the risk factors detailed from time to time in the Company's periodic Securities and Exchange Commission filings, including, without limitation, its 10-K filing for the fiscal year ended December 31, 2012, and the Company's most recent Form 10-Q. By making these forward-looking statements, the Company does not undertake to update them in any manner except as may be required by the Company's disclosure obligations in filings it makes with the Securities and Exchange Commission under the federal securities laws.
|SOURCE MiMedx Group|
Copyright©2012 PR Newswire.
All rights reserved